Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $188M | $203M | $252M | $324M | $393M | $503M |
| Revenue growth | — | — | 8.3% | 24.4% | 28.4% | 21.3% | 27.8% |
| Operating income | — | -$8.20M | -$45.9M | -$82.0M | -$77.0M | -$60.1M | -$36.1M |
| Operating margin | — | -4.4% | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% |
| Net income | — | -$14.3M | -$10.9M | $152K | -$83.1M | -$64.7M | -$60.6M |
| Net margin | — | -7.6% | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
| EPS (diluted) | — | -$0.24 | -$0.16 | -$0.21 | -$0.92 | -$0.71 | -$0.54 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | — | $508K | -$32.7M | -$61.8M | -$36.3M | -$26.5M | -$24.6M |
| Capital expenditures | — | $1.19M | $2.85M | $5.53M | $4.57M | $3.79M | $3.20M |
| Free cash flow | — | -$686K | -$35.5M | -$67.3M | -$40.9M | -$30.3M | -$27.8M |
| Share buybacks | — | — | $0.00 | $9.00M | $1.02M | $0.00 | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.45M | $6.00M | $115M | $14.0M | $33.5M | $49.7M | $33.6M |
| Total assets | $50.0K | $65.7M | $203M | $262M | $209M | $173M | $165M |
| Total liabilities | $27.3K | $37.6M | $99.3M | $138M | $152M | $169M | $180M |
| Long-term debt | — | $6.56M | $0.00 | $80.6M | $86.8M | $93.1M | $77.4M |
| Shareholders' equity | $42.2M | $28.1M | $104M | $123M | $57.0M | $3.59M | -$15.7M |
| Retained earnings | -$2.30K | -$52.3M | -$63.2M | -$63.1M | -$146M | -$211M | -$271M |
| Shares (wtd avg diluted) | 5.75M | 59.1M | 66.2M | 80.6M | 73.7M | 75.0M | 92.4M |
Every figure is extracted from Oncology Institute, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.